NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., March 03, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX ...
Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback